Company intelligence

PTGX

Protagonist Therapeutics, Inc. · NASDAQ · Healthcare

Price$148.18+2.08% · +$3.02

Market cap9.53BEquity value

P / E143.9Trailing ratio

Volume478.04KLatest session

Market data

PTGX price chart

TradingView

Related signals

1 min delayed

Browse public PTGX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

PTGXMar 10, 2025+14.42% since signal

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

PTGX reported positive Phase 2b results for icotrokinra in ulcerative colitis. Icotrokinra showed 63.5% response rate, significantly higher than placebo. Clinical remission rates improved at Week 12 for icotrokinra compared to placebo. Positive Phase 3 data for icotrokinra in psoriasis further boost potential. PTGX stock increased by 35.9% following the announcement.

View signal analysis

Research